Bay­er fronts $65M Se­ries A for Metageno­mi, a gene ther­a­py biotech aim­ing to find new CRISPR en­zymes

Gene edit­ing is all the rage in biotech these days, with the field grow­ing in promi­nence es­pe­cial­ly af­ter this year’s No­bel Prize in Chem­istry was award­ed to two pi­o­neer­ing CRISPR sci­en­tists in Em­manuelle Char­p­en­tier and Jen­nifer Doud­na. And now, Bay­er’s in­vest­ment arm is go­ing all-in on a new gene edit­ing out­fit.

Leaps by Bay­er is co-lead­ing a $65 mil­lion Se­ries A round for Metageno­mi, a biotech launched by UC Berke­ley sci­en­tists that emerged from stealth on Thurs­day. Hum­boldt Fund is co-lead­ing the round with Leaps. Metageno­mi, which will be run by Berke­ley re­searcher Bri­an Thomas, is look­ing to de­vel­op a “tool­box” of both CRISPR- and non-CRISPR-based gene edit­ing sys­tems be­yond the Cas9 pro­tein typ­i­cal­ly seen in the field these days.

Bri­an Thomas

“The goal for Metageno­mi is re­al­ly to be able to do any type of gene edit­ing,” Thomas told End­points News. “Whether that be knock-ins or knock-outs that are com­pa­ra­ble to the cur­rent gene edit­ing ca­pa­bil­i­ties, but al­so to be able to do base edit­ing through an en­gi­neer­ing ca­pa­bil­i­ty, as well as to be able to in­te­grate larg­er pieces of DNA that will al­low us to pro­vide safer gene edit­ing.”

Oth­er in­vestors in the Se­ries A in­clud­ed So­zo Ven­tures, Agent Cap­i­tal, In­Cube Ven­tures and HOF Cap­i­tal.

Dur­ing his time at Berke­ley, Thomas was work­ing in the lab of Jill Ban­field, Metageno­mi’s sci­en­tif­ic co-founder, whose re­search fo­cused on find­ing new CRISPR en­zymes in ex­ot­ic bac­te­ria. Now at Metageno­mi, Thomas’ goal is to ap­ply ma­chine learn­ing on a broad scale to mine through the genomes of these mi­croor­gan­isms, search­ing for new nu­cle­as­es that can be used in gene ther­a­pies.

Thomas says the com­pa­ny has found over 100 po­ten­tial en­zymes in the past year as it’s been build­ing out its data­base in stealth. The main ad­van­tage of these sys­tems, Thomas said, is that many — if not all — are much small­er than Cas9, with some be­ing less than half the size. That would al­low for much more pre­cise med­i­cines that lim­it the off-site tox­i­c­i­ty some­times seen with cur­rent gene ther­a­pies.

“The en­zymes we have are re­al­ly able to out­per­form the cur­rent sys­tems in terms of edit­ing ef­fi­cien­cy,” Thomas said. “We’re get­ting edit­ing ef­fi­cien­cies at greater than 90% and some­times greater than 95%.”

It re­al­ly comes down to the sci­ence of metage­nomics, from which Metageno­mi gets its name, Thomas said. Go­ing be­yond ge­nomics, where you start with a lab cul­ture, metage­nomics in­stead looks at the ge­net­ic ma­te­r­i­al re­cov­ered from soil, which con­tains the thou­sands of or­gan­isms that Metageno­mi hopes to map out.

Juer­gen Eck­hardt

Thomas proved so suc­cess­ful at pitch­ing his com­pa­ny, he poached away one of Leaps’ ex­ec­u­tives to be Metageno­mi’s chief busi­ness of­fi­cer. De­spite that, Bay­er is par­tic­u­lar­ly ex­cit­ed about this start­up and Leaps chief Juer­gen Eck­hardt be­lieves Metageno­mi could be at the fore­front of the next gen­er­a­tion of gene edit­ing.

“You look at gene edit­ing and you have these first-wave com­pa­nies, they are all based on one de­tail: CRISPR Cas9,” Eck­hardt said. “What Metageno­mi has, they are sit­ting on thou­sands of nu­cle­as­es that will have a range of fea­tures that may be op­ti­mized for what CRISPR can’t be able to do. I think that’s why this is the next two, three, four, five waves of gene edit­ing are right here.”

Metageno­mi is still an ear­ly-stage com­pa­ny and Thomas isn’t di­vulging what kinds of drugs they’re aim­ing to de­vel­op as of yet, but not­ed a broad in­ter­est in can­cers and im­muno-on­col­o­gy. On top of that, Metageno­mi’s en­zymes would still need to be paired up with a de­liv­ery sys­tem to get the ther­a­py where it needs to go.

But for now, Metageno­mi will keep plug­ging away in or­der to val­i­date its tech­nol­o­gy. Thomas said that, as a bio­chemist, it’s ex­cit­ing to look at some of these or­gan­isms that have nev­er been seen un­der a mi­cro­scope be­fore that po­ten­tial­ly hold the key to the next cell ther­a­pies.

“Metage­nomics is a very pow­er­ful sci­ence, and I think Metageno­mi is a clear leader in us­ing that sci­ence to de­vel­op and tap in­to this avail­able, nat­ur­al cel­lu­lar ma­chin­ery out there that can be used,” Thomas said. “We’re ex­cit­ed about what na­ture has to of­fer as we dig deep­er in­to this dataset.”

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Ron DePinho (file photo)

A 'fly­over' biotech launch­es in Texas with four Ron De­Pin­ho-found­ed com­pa­nies un­der its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.

Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Eric Kelsic, Dyno Therapeutics CEO

Dyno's Er­ic Kel­sic fills the tank in his quest for bet­ter AAV with a group of big-name sup­port­ers on board

Adeno-associated viruses (AAV) for gene therapy have received a ton of scrutiny throughout the field’s history after a smattering of safety scares and their limited therapeutic range. Hoping to crack the field wide open through a capsid design revolution, Eric Kelsic and his team at Dyno have drummed up immense excitement — and now a hefty war chest.

Dyno Therapeutics has bagged a $100 million Series A with backing from the likes of round leader Andreessen Horowitz and new investor Casdin Capital in its quest to use AI to design better AAV capsids for gene therapy, the company said Thursday.

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate enough to support approval.

Gold­man Sachs jumps aboard Bain-backed 503(b) com­pound­ing phar­ma­cy with a $275M debt loan to sup­ply hos­pi­tals

Long the bane of the FDA’s existence, compounding pharmacies have seen a minor resurgence in the past year as short-term saviors for hospital drug shortages. Now, a 503(b) company specializing in hospital meds has earned a big backer to keep expanding its 200-drug strong portfolio.

Goldman Sachs and Owl Rock Capital Partners have doled out a $275 million debt loan to QuVa Pharma, a 503(b)-certified outsourcing facility providing compounded drugs to hospitals, the company said Thursday.

Bill Lis, Jasper Therapeutics

Jasper and its stem cell con­di­tion­ing an­ti­body earn a tick­et to Nas­daq in lat­est SPAC re­verse merg­er

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Another biotech SPAC deal has landed as the glut of blank-check companies continues to make waves in the industry.

Thursday’s winner is Jasper Therapeutics, joining forces with Amplitude Healthcare Acquisition Corp. in a $100 million reverse-merger, Jasper announced. The deal also comes with a PIPE financing of an additional $100 million, setting Jasper up with a $490 million market cap once the merger closes in the third quarter.

Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saunders went on a tear of headline-blazing deals building Allergan, merging and rearranging a variety of big companies into one before an M&A pact with Pfizer blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so under pressure, he got his buyout at AbbVie — which needed a big franchise like Botox. And it was no big surprise to see him riding the SPAC wave into a recent $1 billion-plus deal that left him in the executive chairman’s seat at an aesthetics outfit — now redubbed The Beauty Health Company — holding a big chunk of the equity.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.